Cargando…
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
Recently, we serendipitously discovered that mice with the deficiency of the enzyme prolylcarboxypeptidase (PRCP) have elevated α-melanocyte-stimulating hormone (α-MSH) levels which lead to decreased food intake and weight loss. This suggests that PRCP is an endogenous inactivator of α-MSH and an ap...
Autores principales: | Shariat-Madar, B, Kolte, D, Verlangieri, A, Shariat-Madar, Z |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916657/ https://www.ncbi.nlm.nih.gov/pubmed/20694162 |
Ejemplares similares
-
Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation
por: Ngo, My-Linh, et al.
Publicado: (2009) -
Daniel Whistler, PRCP
por: Cooke, A. M.
Publicado: (1967) -
Prolylcarboxypeptidase Mitigates Myocardial Ischemia/Reperfusion Injury by Stabilizing Mitophagy
por: Hao, Panpan, et al.
Publicado: (2020) -
Prolylcarboxypeptidase Alleviates Hypertensive Cardiac Remodeling by Regulating Myocardial Tissue Angiotensin II
por: Nguyen, Binh Y., et al.
Publicado: (2023) -
Potential Benefits of Antioxidant Phytochemicals in Type 2 Diabetes
por: Arabshomali, Arman, et al.
Publicado: (2023)